雷贝拉唑比前期上市的其他质子泵抑制剂可以更快速的发挥作用。
Rabeprazole exerts its action much more quickly than the other proton pump inhibitors previously developed.
多种血管生成抑制剂已经在临床前期癌症模型中证实有效，并有几种临床证实有效。
Multiple angiogenesis inhibitors have been therapeutically validated in preclinical cancer models, and several in clinical trials.
应用推荐